VetMedUni biopharmaceutical spinout Marinomed Biotech has completed its IPO to attain a market cap of $109m.

Rob Lavine, News editor for Global Corporate Venturing, reviews the trends in venturing from 2018

Investors including co-founder and Harvard professor Timothy Springer scored exits as mRNA therapy developer Moderna floated in the largest biotech IPO of all time.

Synthorx, spun out of Scripps Research Institute, is targeting $100m in a proposed offering half a year after it raised $63m in a series C round backed by Osage University Partners.

The biopharmaceutical spinout of University of Veterinary Medicine Vienna is issuing 400,000 shares in an initial public offering that is set to fetch between $34m and $41m.

Utec-backed Chiba spinout Autonomous Control Systems Laboratory has filed for an initial public offering on the Tokyo Stock Exchange and plans to list on December 21.

The cybersecurity commercialisation firm hopes to raise $2.9m through an Aim placement and will use the funding for product development, working capital, sales and marketing.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

UCL Technology Fund-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.

Orphan disease drug developer PhaseBio Pharmaceuticals, which is commercialising research from Duke University, cut the price of its shares sharply pre-offering.